t
| Date | 3 Mar 2023 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 7437R |
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
PDMR Dealing
Issue of 33,333,332 Warrants
3 March 2023 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that, further to the Company's announcement on 29 September 2022 regarding the subscription and debt financing, on 28 February 2023 it issued 33,333,332 warrants to subscribe for new Ordinary Shares ("Warrants").
As previously announced, in conjunction with the issue of Loan Notes, the Company agreed to issue 33,333,332 Warrants to Southern Fox and ZQ Capital, to subscribe for new Ordinary Shares at a Warrant Exercise price of 30 pence per Warrant. The Warrants are exercisable for a period of five years from the Purchase Date of the Loan Notes.
Following the issue of Warrants Southern Fox and ZQ Capital will hold the following Warrants over Ordinary Shares in the Company:
· Southern Fox: 16,666,666 Warrants; and
· ZQ Capital: 16,666,666 Warrants.
Capitalised terms used and not defined in this announcement have the meanings given to them in the announcement from 29 September 2022.
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Manuel Llobet, Chief Executive Officer
Martin Hopcroft, Interim Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0)20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.
Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Southern Fox Investments Limited
|
|
|
2 |
Reason for the notification |
|
|
|
a) |
Position/status |
Persons closely associated Mr. Anthony Parker, Non-Executive Director of Allergy Therapeutics Plc. |
|
|
b) |
Initial notification/Amendment |
Initial notification. |
|
|
3 |
Details of the issuer, UK emission allowance market participant, auction platform or auctioneer |
||
|
a) |
Name |
Allergy Therapeutics Plc |
|
|
b) |
LEI |
213800PQ7AHK7KGVOE23 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
|
Warrant Instrument |
|
|
b) |
Nature of the transaction |
Issue of warrants representing subscription rights for ordinary shares of £0.001 each.
|
|
|
c) |
Price(s) and volume(s) |
Exercise Price(s) |
Volume(s) |
|
£0.30 per warrant |
16,666,666 |
||
|
|
|||
|
d) |
Aggregated information · - Aggregated volume · - Price |
n/a |
|
|
e) |
Date of the transaction |
28 February 2023 |
|
|
f) |
Place of the transaction |
Outside a trading venue. |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
ZQ Capital Management Limited |
|
|
2 |
Reason for the notification |
|
|
|
a) |
Position/status |
Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy Therapeutics Plc. |
|
|
b) |
Initial notification/Amendment |
Initial notification. |
|
|
3 |
Details of the issuer, UK emission allowance market participant, auction platform or auctioneer |
||
|
a) |
Name |
Allergy Therapeutics Plc |
|
|
b) |
LEI |
213800PQ7AHK7KGVOE23 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
|
Warrant Instrument |
|
|
b) |
Nature of the transaction |
Issue of warrants representing subscription rights for ordinary shares of £0.001 each.
|
|
|
c) |
Price(s) and volume(s) |
Exercise Price(s) |
Volume(s) |
|
£0.30 (30 pence) per warrant |
16,666,666 |
||
|
|
|||
|
d) |
Aggregated information · - Aggregated volume · - Price |
n/a |
|
|
e) |
Date of the transaction |
28 February 2023 |
|
|
f) |
Place of the transaction |
Outside a trading venue. |
|